| Disease Domain | Count |
|---|---|
| Neoplasms | 2 |
| Top 5 Drug Type | Count |
|---|---|
| Trispecific killer cell engager (TriKE) | 2 |
| Top 5 Target | Count |
|---|---|
| CD16a x IL15R x TEM8 | 1 |
| ADAM17 x CD276 x IL-15Rα | 1 |
Target |
Mechanism ADAM17 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD16a modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
cam1615TEM8 ( CD16a x IL15R x TEM8 ) | Solid tumor More | Preclinical |
TriKE-PACC(University of Minnesota Twin-Cities) ( ADAM17 x CD276 x IL-15Rα ) | Solid tumor More | Preclinical |





